The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting heightened challenges within the genetic testing sector, Myriad Genetics shares plunged 45.72% following a significant downward revision to its 2026 revenue outlook. According to reports, the company now expects revenue between $770 million and $790 million, down from its previous guidance of $860 million to $880 million. This revision stems from weak second-quarter performance and increasing friction with insurance payers.
The company is grappling with competitive pressures and persistent cash burn, with data showing a net loss of $43.2 million for the quarter ending June 30, 2026. Consequently, TD Cowen lowered its price target for the stock to $4, citing operational weaknesses. Per market data, this decline places the company at a disadvantage compared to healthcare and diagnostics peers that maintain faster growth rates and positive profit margins.
Recent price action saw the stock collapse from levels near $5.71 toward the $3.35 and $2.91 range following the guidance cut. As of the August 2, 2026 period, with no updated real-time pricing available, investors are focused on the company's ability to stabilize its financial position. Market participants are also monitoring broader catalysts, including the upcoming OPEC meeting, which may influence general market sentiment.